GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

labetuzumab govitecan   Click here for help

GtoPdb Ligand ID: 8252

Synonyms: hMN-14-SN-38 | hMN-14-SN-38 ADC | IMMU 130 | IMMU-130
Compound class: Antibody
Comment: Labetuzumab govitecan (research code IMMU-130) is an antibody-drug conjugate (ADC) in which the anti-CEACAM5 antibody labetuzumab, is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor irinotecan (as exemplified in patents [2] and [1]).
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical study (NCT01915472) assessing IMMU-130 in patients with metastatic colorectal cancer is in development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01915472 A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2 Interventional Immunomedics, Inc.